A Canadian study provides new evidence for the cost effectiveness of vaccinating boys for the human papilloma virus (HPV) to prevent oral cancer.
First licensed for use in 2006, the HPV vaccine is now recommended in several Western countries for girls aged 9 to 12 as a cost-effective measure in the prevention of cervical cancer.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
